Company Overview

Mirum Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare pediatric liver diseases. The company operates within the biotechnology and specialty pharmaceuticals industry, with an emphasis on cholestatic liver disorders that have limited or no approved treatment options. Mirum’s business model centers on developing bile acid modulation therapies designed to address the underlying drivers of these rare conditions rather than only managing symptoms.

The company’s primary revenue drivers are its approved therapeutics Livmarli (maralixibat) and Bylvay (odevixibat), both indicated for rare cholestatic liver diseases. Mirum primarily serves pediatric and specialty hepatology markets, working closely with specialized physicians and treatment centers. Founded in 2018 and headquartered in the United States, Mirum evolved rapidly from a development-stage company to a commercial organization following regulatory approvals and the strategic acquisition of Albireo Pharma, which significantly expanded its product portfolio and global reach.

Business Operations

Mirum generates revenue through the commercialization of its approved products across the United States and international markets. Its core operating segments are centered on rare liver disease therapeutics, with Livmarli approved for Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC), and Bylvay approved for PFIC and Alagille syndrome in multiple jurisdictions. The company also maintains a clinical development pipeline targeting additional cholestatic indications and age groups.

Operations include in-house commercialization capabilities, regulatory affairs, and clinical development, supported by a network of third-party manufacturers and distributors. Mirum conducts both domestic and international operations, leveraging regional partners in certain ex-U.S. markets. Through the acquisition of Albireo Pharma, Mirum gained full global rights to Bylvay and expanded its European commercial infrastructure, strengthening its ability to serve international patient populations.

Strategic Position & Investments

Mirum’s strategic direction is focused on becoming a global leader in rare liver disease therapeutics by maximizing the lifecycle value of its approved products and expanding into additional indications. Growth initiatives include label expansions, geographic expansion into underserved markets, and continued investment in clinical development programs aimed at earlier-stage and broader patient populations.

A major strategic milestone was the acquisition of Albireo Pharma, which added Bylvay to Mirum’s portfolio and created a complementary franchise alongside Livmarli. The company continues to invest in clinical research, post-marketing studies, and regulatory expansion while evaluating opportunities to in-license or acquire additional rare disease assets that align with its core expertise in hepatology.

Geographic Footprint

Mirum is headquartered in North America, with its principal executive offices in the United States. The company maintains a significant commercial presence in the U.S., which represents its largest revenue-generating market. Through direct operations and partnerships, Mirum also has an established footprint in Europe, where Bylvay is approved and commercialized in multiple countries.

Beyond the U.S. and Europe, Mirum has extended its reach into additional international markets through regulatory approvals, distribution agreements, and named patient programs. This global operating model allows the company to address rare disease populations across multiple continents while maintaining centralized strategic and operational control.

Leadership & Governance

Mirum is led by an experienced executive team with backgrounds in rare disease commercialization, drug development, and public company governance. The leadership team emphasizes a patient-focused strategy, disciplined capital allocation, and long-term value creation through scientific innovation and operational execution.

Key executives include:

• Chris Peetz – President and Chief Executive Officer
• Peter Radovich – Chief Financial Officer
• Pamela Stephenson – Head of Legal and Corporate Affairs
• Richard Jones – Chief Commercial Officer
• Giorgio Rovati – Chief Medical Officer

The company is governed by a board of directors with experience in biotechnology, pharmaceuticals, and healthcare investing, supporting Mirum’s strategic vision to address unmet needs in rare liver diseases while operating as a compliant U.S. public company under SEC filings and related regulatory frameworks.